科迪亚克的Zenkuda药物满足了糖尿病视网膜病症的主要试验目标,提高投资者的信心. Kodiak's Zenkuda drug met key trial targets for diabetic retinopathy, boosting investor confidence.

在该公司药物Zenkuda在糖尿病视网膜病变晚期试验中达到主要终点后, Kodiak Sciences的股价升. Kodiak Sciences shares surged after its drug Zenkuda met primary endpoints in a late-stage diabetic retinopathy trial. 治疗显著改善了疾病严重程度,并减少了视力危害的并发症,具有强大的安全性. The treatment showed significant improvement in disease severity and reduced sight-threatening complications, with a strong safety profile. 公司计划加快监管提交,提高投资者的信心. The company plans to accelerate regulatory submissions, boosting investor confidence.